TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20184577
Drug: UK-369,003 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK-369,003 100 mg MR
Study: 17578979
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg preoperatively and 200 mg every 12 h postoperatively
Study: 11890384
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine, body therapy (somatic therapy, bodywork), and guided imagery for 6 months
Study: 11890384
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine, body therapy, and guided imagery
Study: 9567734
Drug: Stimulus control
Normalized name: Limulus polyphemus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulus control treatment and withdrawal program (medicated participants)
Study: 9567734
Drug: Stimulus control
Normalized name: Limulus polyphemus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulus control treatment (nonmedicated participants)
Study: 9567734
Drug: Stimulus control
Normalized name: Limulus polyphemus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulus control treatment (medicated participants)
Study: 7608644
Drug: Intra-uterine device,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-uterine device, condom, progestogen-only pill (alternative birth-control methods)
Study: 2240632
Drug: Anesthesia including
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesia including nitrous oxide (N2O) (50%-60%) during regional anesthesia supplemented with isoflurane and intravenous adjuvants
Study: 2240632
Drug: Anesthesia excluding
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesia excluding nitrous oxide (N2O) during regional anesthesia supplemented with isoflurane and intravenous adjuvants
Study: 28851171
Drug: GnRH‐a (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH‐a (0.1 mg subcutaneous injection)
Study: 28851171
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% saline 2 ml subcutaneous injection)
Study: 23578980
Drug: Salbutamol nebulizer
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol nebulizer 1250 μg three times a day
Study: 18650630
Drug: Standard parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard parenteral nutrition (n = 49)
Study: 18650630
Drug: Immunomodulating parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunomodulating parenteral nutrition (n = 51)
Study: 17312651
Drug: Metered Dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered Dose Inhaler with accessory device (MDI/AD)
Study: 14552819
Drug: Impact of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impact of 6MP dose on metabolite concentrations.
Study: 15817423
Drug: Antiretroviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral treatment (ART) interruptions for at least two weeks
Study: 15817423
Drug: Treatment interruptions
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment interruptions (TI)
Study: 10917355
Drug: Staged therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Staged therapy treating the entire volume to 10 Gy twice for AVMs with a volume of more than 25 cc
Study: 1696438
Drug: Astemizole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole (20 mg BID for three days)
Study: 1696438
Drug: Placebo of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of astemizole (twice a day for three days)
Study: 31841482
Drug: Pathogenetic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pathogenetic treatment of the digestive tract
Study: 23981904
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g CaHMB consumed twice daily
Study: 19533025
Drug: Carmustine (BCNU)
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carmustine (BCNU) and conformal irradiation (dose levels: 66, 72, 78, 84 Gy)
Study: 17276051
Drug: 100 mcg
Normalized name: Levo-T 100 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mcg levosalbutamol
Study: 17276051
Drug: 200 mcg
Normalized name: CrM 200 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mcg salbutamol
Study: 9272426
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg estradiol valerate combined with 75 micrograms levonorgestrel
Study: 9272426
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg medroxyprogesterone acetate (MPA)
Study: 30975196
Drug: Curcumin 500-mg
Normalized name: curcumin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin 500-mg capsule three times daily
Study: 30975196
Drug: Diclofenac 50-mg
Normalized name: diclofenac sodium 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 50-mg tablet two times daily
Study: 16172147
Drug: Two etonogestrel
Normalized name: Etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two etonogestrel rods (204 mg etonogestrel) and 400 mg testosterone decanoate every 4 weeks (group I, n = 42)
Study: 16172147
Drug: Two etonogestrel
Normalized name: Etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two etonogestrel rods (204 mg etonogestrel) and 400 mg testosterone decanoate every 6 weeks (group II, n = 51)
Study: 16172147
Drug: Two etonogestrel
Normalized name: Etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two etonogestrel rods (204 mg etonogestrel) and 600 mg testosterone decanoate every 6 weeks (group III, n = 37)
Study: 14669843
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg estradiol valerate (E2V) + 3 mg dienogest (DNG)
Study: 11079281
Drug: 20 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 minutes of education on the use of a metered-dose inhaler (MDI)-spacer device
Study: 8646142
Drug: Pituitary suppression
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pituitary suppression with a luteinising hormone releasing hormone analogue followed by low dose ovulation induction and luteal phase progesterone
Study: 24754328
Drug: Oral prenatal
Normalized name: Ardisia crenata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prenatal probiotic (Florajen3) taken once daily
Study: 9862412
Drug: Oxygen administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen administration 5 min prior to word presentation
Study: 9862412
Drug: Oxygen administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen administration immediately before word presentation
Study: 9862412
Drug: Oxygen administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen administration immediately following word presentation
Study: 9862412
Drug: Oxygen administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen administration 10 min prior to word presentation
Study: 9862412
Drug: Oxygen administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen administration 5 min following word presentation
Study: 9862412
Drug: Oxygen administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen administration 10 min following word presentation
Study: 9862412
Drug: Oxygen administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen administration for 2 min during the experiment
Study: 7638804
Drug: Nebulised morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised morphine (10 mg)
Study: 7638804
Drug: Nebulised morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised morphine (25 mg)
Study: 7638804
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (1 mg)
Study: 7638804
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (2.5 mg)
Study: 2692816
Drug: Theophylline (5.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (5.5 mg of the ethylendiamine salt.kg‐1 intravenously)
Study: 31508863
Drug: Tramadol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (1 mg/kg) with paracetamol (1 g)
Study: 25209313
Drug: Patient self-testing
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient self-testing (PST) weekly
Study: 25209313
Drug: Patient self-testing
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient self-testing (PST) twice weekly
Study: 23638622
Drug: Raloxifene hydrochloride
Normalized name: Raloxifene Hydrochloride
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene hydrochloride (60 mg/day) for 12 weeks
Study: 21205325
Drug: Polypill (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypill (75 mg aspirin, 20 mg simvastatin, 10 mg lisinopril, 12.5 mg hydrochlorothiazide)
Study: 21205325
Drug: Standard Practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Practice (individual drugs)
Study: 19419544
Drug: Traditional antiepileptic
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional antiepileptic drugs
Study: 16968583
Drug: Fixed-combination of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-combination of dorzolamide/timolol (DTFC; dorzolamide 2.0%/timolol maleate 0.5%)
Study: 15367414
Drug: Myocet (M;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myocet (M; 75 mg/m(2)) + cyclophosphamide (C; 600 mg/m(2))
Study: 15367414
Drug: Epirubicin (E;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (E; 75 mg/m(2)) + cyclophosphamide (C; 600 mg/m(2))
Study: 11967795
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (2-32 mg) over a median period of 84 days (range: 1-418 days)
Study: 9174296
Drug: alfentanil 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfentanil 40 microg/kg followed by propofol 2 mg/kg
Study: 9174296
Drug: alfentanil 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfentanil 40 microg/kg followed by etomidate 0.3 mg/kg
Study: 9174296
Drug: alfentanil 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfentanil 40 microg/kg followed by thiopental 4 mg/kg
Study: 9174296
Drug: d-tubocurarine 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-tubocurarine 3 mg followed by thiopental 4 mg/kg and succinylcholine 1 mg/kg
Study: 8465885
Drug: Buspirone added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone added to fluvoxamine therapy
Study: 3763655
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg penbutolol and 3 mg piretanide
Study: 29780062
Drug: Chlorella (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorella (6 g/day)
Study: 29780062
Drug: Placebo (7.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (7.2 g/day lactose)
Study: 26807672
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg intravenously over 40 min)
Study: 25264974
Drug: WEBCARE (12-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: WEBCARE (12-week fixed, six-lesson behavioral treatment based on cognitive behavioral therapy)
Study: 19898831
Drug: Exenatide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (5 microg subcutaneous)
Study: 12425803
Drug: Pantoprazole triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole triple regimen (pantoprazole 40 mg, amoxicillin 1 g, metronidazole 400 mg, bid, for 1-week)
Study: 12425803
Drug: Omeprazole triple
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole triple regimen (omeprazole 20 mg, amoxicillin 1 g, metronidazole 400 mg, bid, for 1-week)
Study: 12425803
Drug: Pantoprazole triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole triple regimen (pantoprazole 40 mg, amoxicillin 1 g, metronidazole 400 mg, bid, for 2-weeks)
Study: 12425803
Drug: Omeprazole triple
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole triple regimen (omeprazole 20 mg, amoxicillin 1 g, metronidazole 400 mg, bid, for 2-weeks)
Study: 7047341
Drug: Oxmetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxmetidine (400 mg b.i.d.)
Study: 23361158
Drug: Cholecalciferol (50,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (50,000 IU weekly for 12 weeks followed by 50,000 IU every other week for 40 weeks)
Study: 17047649
Drug: Weekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly cisplatin (30 mg/m²), epirubicin (50 mg/m²), and paclitaxel (120 mg/m²) with granulocyte-colony stimulating factor support (PET)
Study: 17047649
Drug: Tri-weekly epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tri-weekly epirubicin (90 mg/m²) and paclitaxel (175 mg/m²) (ET)
Study: 17047649
Drug: Weekly cisplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly cisplatin, epirubicin, and paclitaxel (PET)
Study: 17047649
Drug: Tri-weekly epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tri-weekly epirubicin and paclitaxel (ET)
Study: 11760527
Drug: Injection speed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection speed of 10 s/cc
Study: 11760527
Drug: Injection speed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection speed of 30 s/cc
Study: 8161675
Drug: Single-dose sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose sodium phosphate solution regimen (Fleet Phospho-Soda)
Study: 3745848
Drug: Regular coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular coffee (100 ml)
Study: 3745848
Drug: Decaffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decaffeinated coffee (100 ml)
Study: 3745848
Drug: Sugared water
Normalized name: SUGAR/WATER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugared water (100 ml)
Study: 3745848
Drug: Regular coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular coffee (50 ml)
Study: 20609130
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (BoNT‐A) administered intradermally and subcutaneously, 5 units/site, total dose 40-200 units.
Study: 15855884
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy (estrogen and gestagen)
Study: 10806378
Drug: Fluoroquinolone antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoroquinolone antibiotics (FQ)
Study: 8638526
Drug: Nitrates alone
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrates alone or in combination with hydralazine
Study: 8638526
Drug: Intermittent dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent dosing of nitrates
Study: 8638526
Drug: Escalating dose
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating dose regimen of nitrates with hydralazine
Study: 1503483
Drug: Modified FAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified FAM (5-FU + ADR + MMC) therapy
Study: 1503483
Drug: 5-FU mono-therapy
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU mono-therapy
Study: 6476623
Drug: Intermittent rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent rectal diazepam (0.5 mg/kg every 8 hours during fever)
Study: 6476623
Drug: Oral phenobarbital
Normalized name: phenobarbital Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral phenobarbital (BID)
Study: 29533112
Drug: Focused ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focused ultrasound treatment
Study: 26854906
Drug: MVA85A-IMX313 (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA85A-IMX313 (low dose)
Study: 26854906
Drug: MVA85A-IMX313 (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA85A-IMX313 (standard dose)
Study: 17177960
Drug: Nicotine (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (7 mg transcutaneous patch)
Study: 16000961
Drug: Low-dose IL-2
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IL-2 (3 x 10(6) IU/m2/d) administered subcutaneously for 42 days
Study: 12387527
Drug: N 25
Normalized name: oxygen 25 %
Approvals — FDA: no, EMA: no, PMDA: no
Description: N 25 mg
Study: 12387527
Drug: N 50
Normalized name: Ovcon 50
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: N 50 mg
Study: 8137624
Drug: GES/EE (gestodene
Approvals — FDA: no, EMA: no, PMDA: no
Description: GES/EE (gestodene 75 mcg/ethinyl oestradiol 30 mcg)
Study: 8137624
Drug: DES/EE (desogestrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: DES/EE (desogestrel 150 mcg/ethinyl oestradiol 20 mcg)
Study: 2536537
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of calcitriol
Study: 2536537
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of active forms of vitamin D3
Study: 22995539
Drug: E(2)V/DNG oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: E(2)V/DNG oral contraceptive
Study: 21774987
Drug: 12-month socioculturally
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month socioculturally adapted collaborative care (psychotherapy and/or antidepressants, telephone symptom monitoring/relapse prevention)
Study: 19631861
Drug: PTFE ACUSEAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTFE ACUSEAL patch
Study: 19631861
Drug: Hemashield Finesse
Normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hemashield Finesse patch
Study: 19631861
Drug: PTFE ACUSEAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTFE ACUSEAL patch and Hemashield Finesse patch
Study: 15213476
Drug: Structured nursing
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured nursing intervention (12 consecutive weekly meetings)
Study: 9641732
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily growth hormone injection (group A)
Study: 9641732
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily growth hormone injections (group B)
Study: 7853436
Drug: Mebendazole treatment
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mebendazole treatment in Group A
Study: 7853436
Drug: Mebendazole treatment
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mebendazole treatment in Group B
Study: 7853436
Drug: Mebendazole treatment
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mebendazole treatment in Group C
Study: 2910422
Drug: Infusor (Baxter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusor (Baxter Healthcare Corporation) for outpatient CVI chemotherapy
Study: 2910422
Drug: Standard inpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard inpatient CVI chemotherapy delivery device (standard pump)
Study: 2910422
Drug: Infusor (Baxter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusor (Baxter Healthcare Corporation) for inpatient CVI chemotherapy
Study: 2910422
Drug: Outpatient CVI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient CVI chemotherapy
Study: 2910422
Drug: CVI chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVI chemotherapy (both methods)
Study: 1130305
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplementation (small daily dose)
Study: 22959620
Drug: Synbiotic (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic (6 g, two daily doses)
Study: 21292332
Drug: Steroid antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid antibiotic pack (Betnovate-N: betnovate sodium phosphate 0.1% and neomycin sulphate 0.5%)
Study: 19479252
Drug: GIPET-enhanced oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIPET-enhanced oral acyline 10 mg
Study: 19479252
Drug: GIPET-enhanced oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIPET-enhanced oral acyline 20 mg
Study: 19479252
Drug: GIPET-enhanced oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIPET-enhanced oral acyline 40 mg
Study: 26356398
Drug: Baclofen (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (50 mg/day) for 3 months
Study: 21547598
Drug: BMMC +
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMMC + CRTinact (BMMC therapy only)
Study: 21547598
Drug: BMMC +
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMMC + CRTact (BMMC therapy + CRT)
Study: 16161123
Drug: Lyophilized bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized bone chips supplemented with platelet gel (PG)
Study: 16161123
Drug: Lyophilized bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized bone chips without gel
Study: 11100985
Drug: intra-arterial chemotherapy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intra-arterial chemotherapy
Study: 11100985
Drug: systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: systemic chemotherapy
Study: 11100985
Drug: multimodality combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: multimodality combination and sequential treatment
Study: 8960716
Drug: Physostigmine (18,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (18, 24, or 30 mg daily)
Study: 19959493
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH; 5000 IU twice daily)